BioNTech SE Announces Collaboration with Bristol Myers Squibb
Ticker: BNTX · Form: 6-K · Filed: 2025-06-02T00:00:00.000Z
Sentiment: neutral
Topics: collaboration, partnership, biotech
TL;DR
BNTX teams up with BMY, details TBD.
AI Summary
On June 2, 2025, BioNTech SE (BNTX) and Bristol Myers Squibb (BMY) announced a collaboration. The specific details of this collaboration, including any financial terms or project scope, are not provided in this filing.
Why It Matters
This announcement signals potential future developments and partnerships for BioNTech, which could impact its research pipeline and market position.
Risk Assessment
Risk Level: low — The filing is an announcement of a collaboration without immediate financial implications or significant new disclosures.
Key Players & Entities
- BioNTech SE (company) — Registrant and collaborator
- Bristol Myers Squibb (company) — Collaborator
- BNTX (company) — Ticker symbol for BioNTech SE
- BMY (company) — Ticker symbol for Bristol Myers Squibb
- June 2, 2025 (date) — Date of announcement
FAQ
What is the nature of the collaboration between BioNTech SE and Bristol Myers Squibb?
The filing announces that BioNTech SE and Bristol Myers Squibb have entered into a collaboration, but does not provide specific details about its nature.
When was this collaboration announced?
The collaboration was announced on June 2, 2025.
Are there any financial terms disclosed for this collaboration?
No financial terms or dollar amounts related to the collaboration are disclosed in this filing.
What are the ticker symbols for BioNTech SE and Bristol Myers Squibb?
The ticker symbol for BioNTech SE is BNTX, and for Bristol Myers Squibb is BMY.
Does this filing provide information on specific projects or research areas for the collaboration?
No, this filing only announces the collaboration and does not specify any projects or research areas.
From the Filing
0001776985-25-000039.txt : 20250602 0001776985-25-000039.hdr.sgml : 20250602 20250602072006 ACCESSION NUMBER: 0001776985-25-000039 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250602 FILED AS OF DATE: 20250602 DATE AS OF CHANGE: 20250602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251013128 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kbnt3272jun2025.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On June 2, 2025, BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. The press release and related presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Ugur Sahin By: /s/ Dr. Sierk Poetting Name: Ugur Sahin Name: Dr. Sierk Poetting Title: Chief Executive Officer Title: Chief Operating Officer Date: June 2, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types 99.2 A Transformative Global Partnership for BNT327 EX-99.1 2 a991250602_bntxxbmsxprxcol.htm EX-99.1 Document Exhibit 99.1 BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-D evelop and Co- Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types • BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types • The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners’ expertise, resources and global footprint to accelerate BNT327’s path towards potential regulatory approvals and market launches • BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance B NT327 across numerous solid tumor types MAINZ, Germany